New Ellis (NUWE) Q2 2025: Pediatric Revenue Climbs 23% as Manufacturing Transition Targets Cost Relief
New Ellis’ Q2 was defined by a temporary supply chain disruption and a decisive pivot in investment focus, with pediatric segment growth standing out amid broader headwinds. The company’s rapid resolution of a sterilization vendor issue and reallocation of clinical trial funding underscore a disciplined approach to capital and operational priorities. With manufacturing transition and outpatient heart failure opportunities in focus, execution in the second half will test the sustainability of these strategic shifts.
Summary
- Pediatric Segment Momentum: Pediatric revenue growth outpaced other segments, highlighting the company’s differentiated position in fluid management for children.
- Strategic Resource Reallocation: Termination of the reverse HF trial frees capital for nearer-term commercial priorities.
- Manufacturing Transition Watchpoint: Move to KDI manufacturing in October is positioned to drive cost efficiencies but operational delivery remains key.
Performance Analysis
New Ellis’ Q2 revenue declined sharply year-over-year, pressured by a sterilization vendor disruption that delayed approximately $400,000 in sales, primarily impacting the heart failure and critical care segments. Pediatric revenue, representing a smaller but strategically important portion of the business, increased 23% year-over-year, benefiting from prioritized inventory allocation and continued demand from children’s hospitals. Heart failure and critical care revenues fell 53% and 35%, respectively, underscoring the outsized impact of the supply chain bottleneck and the company’s exposure to single-source vendors.
Gross margin compressed to 55.5% from 67.2% in the prior year, driven by underabsorption of fixed overhead due to lower production volumes. Operating expenses remained tightly managed, with SG&A flat and R&D up modestly, yet operating loss widened to $2.9 million. The company ended the quarter with $4.5 million in cash and bolstered its liquidity with a recent $5 million capital raise, maintaining a debt-free balance sheet and providing runway for planned investments.
- Pediatric Growth Outpaces Headwinds: Pediatric segment resilience and new hospital adoption provided a rare bright spot.
- Margin Compression Driven by Volume Shortfall: Lower production volumes led to underabsorption of fixed costs and pressured gross margin.
- Capital Raise Shifts Liquidity Profile: The $5 million gross capital raise provides flexibility for near-term initiatives despite ongoing losses.
While the sterilization issue is resolved and inventory is recovering, the quarter’s results reinforce the company’s sensitivity to operational disruptions and the importance of execution on its manufacturing transition and commercial priorities.
Executive Commentary
"Due to an industry-wide issue with our sterilization vendor, we experienced a temporary backorder of approximately $400,000 in revenue. During this time, our team acted quickly and decisively to prioritize our pediatric patients, ensuring that our most vulnerable patients received access to our life-saving therapy...in the first week of July, we fully reconciled this backorder and are no longer in backorder. This gives us a strong footing in entering Q3."
John Erb, Chairman of the Board and Chief Executive Officer
"Gross margin for the quarter was 55.5% compared to 67.2% in Q2 2024. The margin impact was largely due to underabsorption of fixed overhead because of lower production volumes. ...The recent $5 million gross capital raise bolsters our financial position and provides us with flexibility to support our core growth initiatives."
Rob Scott, Chief Financial Officer
Strategic Positioning
1. Pediatric and Cardiac Surgery as Growth Pillars
Pediatrics remains the company’s most resilient and differentiated segment, with Aquadex, ultrafiltration device for fluid management, offering a rare FDA-cleared solution for children as small as 20 kilograms. The company continues to add new children’s hospitals, strengthening its reputation and deepening clinical adoption. In cardiac surgery, Aquadex is gaining traction for post-operative fluid management, with physicians citing faster ventilator weaning and ICU discharge, supporting the device’s clinical utility and value proposition.
2. Outpatient Heart Failure Opportunity Accelerates
Leadership is increasingly focused on the outpatient heart failure market, where recent reimbursement increases—from $413 to $1,639 per day—are driving hospital interest in setting up dedicated clinics. The company has already supported its first outpatient treatment under the new reimbursement regime, and sees this as a “faster growing area” with meaningful commercial upside as more hospitals activate these clinics.
3. Manufacturing Transition to KDI for Cost Efficiency
New Ellis is moving manufacturing to KDI Precision Manufacturing with a planned October go-live. This transition is expected to deliver operational efficiencies and cost savings over the next 12 months, but execution risk remains as the company must balance inventory build, quality, and uninterrupted supply during the switchover.
4. Capital Discipline and Clinical Focus
The decision to terminate the reverse HF post-market trial, reallocating $4 million to higher-impact areas, signals a clear shift toward commercial execution over long-cycle clinical evidence generation in heart failure. Leadership is prioritizing investments that can drive near-term revenue and margin improvement, rather than incremental inpatient indications.
Key Considerations
This quarter’s results and management actions highlight a company at a strategic crossroads, balancing operational recovery with targeted investment in growth segments and cost structure transformation.
Key Considerations:
- Pediatric Segment Resilience: Sustained demand and new hospital wins reinforce Aquadex’s clinical differentiation in pediatrics.
- Outpatient Heart Failure Reimbursement Catalysts: Higher reimbursement rates are driving hospital engagement, but program activation and patient volume ramp are key watchpoints.
- Manufacturing Transition Execution Risk: The October shift to KDI must deliver promised cost savings without supply interruptions.
- Capital Reallocation Discipline: Termination of the reverse HF trial reflects a pragmatic focus on investments with clearer commercial returns.
Risks
Operational risk remains elevated as the company executes its manufacturing transition, with any delay or quality issue potentially impacting revenue and margin. The business is also exposed to reimbursement changes and slow adoption in the outpatient heart failure segment. Liquidity, while improved, remains a watchpoint given ongoing losses and the need for sustained execution to approach cash flow breakeven.
Forward Outlook
For Q3 2025, New Ellis expects:
- Resolution of sterilization backlog to support normalized revenue flow.
- Continued growth in pediatric and outpatient heart failure segments as new clinics come online.
For full-year 2025, management maintained a disciplined approach, emphasizing:
- Completion of KDI manufacturing transition by October.
- Focus on driving commercial adoption in pediatrics, cardiac surgery, and outpatient heart failure.
Management highlighted several factors that will shape results:
- Execution on manufacturing transition and inventory build.
- Ramp-up of outpatient heart failure clinics under new reimbursement rates.
Takeaways
New Ellis’ Q2 was a test of operational agility and capital discipline, with pediatric demand and reimbursement tailwinds in heart failure providing a path forward. Investors should monitor:
- Execution on Manufacturing Transition: Cost savings and supply reliability from KDI move are critical to margin improvement and growth enablement.
- Pediatric and Outpatient Clinic Ramp: Sustained hospital onboarding and clinic activation will be the main drivers of revenue recovery and future upside.
- Capital Allocation Discipline: Continued focus on high-return investments and cost control will be essential as the company works toward cash flow breakeven.
Conclusion
New Ellis enters the second half of 2025 with a reset operational base, a sharper focus on its strongest clinical segments, and a major manufacturing transition underway. The company’s ability to execute on these priorities will determine whether recent strategic pivots translate into sustained growth and improved financial health.
Industry Read-Through
The quarter underscores the vulnerability of small medtech firms to supply chain disruptions, especially those reliant on single-source vendors for critical processes like sterilization. The rapid shift in reimbursement for outpatient heart failure treatments signals an evolving payer landscape that could benefit device makers able to support hospital clinic buildouts. Capital discipline and targeted investment in high-impact segments are likely to become more prominent themes across the medtech sector, as companies balance clinical evidence generation with commercial execution under tightening capital markets.